Efficacy and Safety of Induction Chemoimmunotherapy Followed by Carbon Ion Radiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
Sponsor study identifier
observational
34
1 country
1
Study Start
June 16, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 15, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is the first prospective clinical study to evaluate the efficacy and safety of induction chemoimmunotherapy followed by carbon ion radiotherapy and consolidation immunotherapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Based on this prospective study, tumor tissue, blood, urine, and stool samples from participants will be collected and analyzed to identify predictive markers of treatment response.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 16, 2025
Actual (reported)June 16, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 25, 2025
Actual (reported)June 15, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
1-year PFS
Time between enrollment and recurrence of disease or death
12 months
Incidence of Grade ≥3 Treatment-Related Adverse Events
Safety
Occurrence or end of follow-up（3 years after enrollment), which comes first
OS
Occurrence or end of follow-up（3 years after enrollment）, which comes first
Biomarker Analysis
36 months
Patients will receive platinum-based doublet chemotherapy and immunotherapy, followed by carbon iron radiotherapy and immunotherapy. The concrete immune checkpoint inhibitor includes durvalumab, sugemalimab, atezolizumab, benmelstobart, pembrolizumab, camrelizumab, toripalimab, tislelizumab, sintilimab, nivolumab, serplulimab, or penpulimab.
platinum-based doublet chemotherapy
Patients with unresectable locally advanced non-small cell lung cancer (according to the 8th edition of the AJCC staging system).
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
tumor tissue, blood, urine, and stool samples
Yongling JI, MD
Zhejiang Cancer Hospital
First Submitted
June 16, 2025
First Posted
June 25, 2025
Study Start
June 16, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 15, 2027
Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma
The concrete immune checkpoint inhibitor includes durvalumab, sugemalimab, atezolizumab, benmelstobart, pembrolizumab, camrelizumab, toripalimab, tislelizumab, sintilimab, nivolumab, serplulimab, or penpulimab.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
June 25, 2025
Record last verified: 2025-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: